Skip to content
The Nexus
DossierENTITY

Alpha-1 Antitrypsin Deficiency

Coverage of Alpha-1 Antitrypsin Deficiency in the Nexus archive.

Earliest in view: Jun 23 · 11:30 UTCMost recent: Jun 23 · 11:30 UTC
Co-mentioned in this coverage
Serapha Bioorganization1RA Capitalorganization1RTW Investmentsorganization1Boundless Bioorganization1Chinese drug companyorganization1
Recent coverage
  • HEALTHJun 23 · 11:30 UTCSTAT NEWS
    STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

    Serapha Bio, a gene-editing startup, secured $230 million in funding and a Chinese licensing deal through a reverse merger with Boundless Bio. The company aims to develop a one-time treatment for Alpha-1 Antitrypsin Deficiency (AATD), a liver and lung disease, with founding investors RA Capital and RTW Investments.

Alpha-1 Antitrypsin Deficiency · Dossier · The Nexus